SIGA SIGA Technologies, Inc.
USHealthcareAs of 2026-07-10 16:00
Why SIGA matters now
SIGA Technologies, Inc. (SIGA) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.59 with +2.57% on the session and $257.5M in market capitalization; recent performance reads 1-month -1.14% and YTD -29.30%.
The latest financial table shown here is Q1 2026, with revenue of $6.2M, net income of $-3.5M, and EPS of $-0.05. Investors can compare that operating picture with valuation signals such as P/E 13.92 and FCF yield 8.8%.
The latest indexable market news headline is "Siga Technologies Q1 Earnings Call Highlights" from MarketBeat.
Additional event context on this page matters because analyst consensus is available with a median target of $—; recent insider activity includes Nabel Gary J. filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
13.92
PEG
—
P/B
2.04
P/S
3.30
EV/EBITDA
6.00
DCF Value
$10.31
FCF Yield
8.8%
Div Yield
13.9%
Margins & Returns
Gross Margin
65.4%
Operating Margin
22.0%
Net Margin
21.6%
ROE
10.6%
ROA
9.2%
ROIC
10.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $6.2M | $-3.5M | $-0.05 |
| Q4 2025 | $3.8M | $-5.4M | $-0.08 |
| FY 2025 | $94.6M | $23.3M | $0.33 |
| Q3 2025 | $2.6M | $-6.4M | $-0.09 |
Analyst Ratings
Consensus
—
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
0.85
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.